2024/03/11 更新

写真a

スギタ シンジ
杉田 慎二
Sugita Shinji
所属
武蔵小杉病院 麻酔科 准教授
職名
准教授
外部リンク

研究分野

  • ライフサイエンス / 麻酔科学

論文

  • Intraoperative cardiac arrest caused by unexpected vasospastic angina requiring prolonged resuscitation using extracorporeal membrane oxygenation: a case report. 国際誌

    Shinji Sugita, Masanobu Obata, Fumihiko Hasunuma, Atsuhiro Sakamoto

    JA clinical reports   9 ( 1 )   77 - 77   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Vasospastic angina (VSA) occurring during surgery is rare but can lead to sudden intraoperative cardiac arrest. CASE PRESENTATION: A 77-year-old man with hypertension, and no history of coronary artery disease, displayed an abrupt ST-segment elevation on the electrocardiogram (ECG) during laparoscopic inguinal hernia surgery under general anesthesia. Subsequently, ventricular fibrillation (VF) occurred, with a finding suggesting ischemic myocardial contracture by transesophageal echocardiography. VF was refractory to cardiopulmonary resuscitation (CPR), and veno-arterial extracorporeal membrane oxygenation (VA ECMO) was introduced. Spontaneous circulation resumed 77 min post-cardiac arrest. VSA was confirmed through the patient's clinical course and coronary angiography. Subsequently, VA ECMO was terminated, and the patient was discharged uneventfully. CONCLUSIONS: Extracorporeal CPR may be a valuable alternative to extended resuscitation for refractory ventricular arrhythmias by VSA.

    DOI: 10.1186/s40981-023-00667-z

    PubMed

    researchmap

  • Intraoperative serum lactate levels as a prognostic predictor of outcome for emergency abdominal surgery: a retrospective study. 査読 国際誌

    Shinji Sugita, Masashi Ishikawa, Takahiro Sakuma, Masumi Iizuka, Sayako Hanai, Atsuhiro Sakamoto

    BMC surgery   23 ( 1 )   162 - 162   2023年6月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The relationship between intraoperative lactate levels and prognosis after emergency gastrointestinal surgery remains unclear. The purpose of this study was to investigate the prognostic value of intraoperative lactate levels for predicting in-hospital mortality, and to examine intraoperative hemodynamic managements. METHODS: We conducted a retrospective observational study of emergency GI surgeries performed at our institution between 2011 and 2020. The study group comprised patients admitted to intensive care units postoperatively, and whose intraoperative and postoperative lactate levels were available. Intraoperative peak lactate levels (intra-LACs) were selected for analysis, and in-hospital mortality was set as the primary outcome. The prognostic value of intra-LAC was assessed using logistic regression and receiver operating characteristic (ROC) curve analysis. RESULTS: Of the 551 patients included in the study, 120 died postoperatively. Intra-LAC in the group who survived and the group that died was 1.80 [interquartile range [IQR], 1.19-3.01] mmol/L and 4.22 [IQR, 2.15-7.13] mmol/L (P < 0.001), respectively. Patients who died had larger volumes of red blood cell (RBC) transfusions and fluid administration, and were administered higher doses of vasoactive drugs. Logistic regression analysis showed that intra-LAC was an independent predictor of postoperative mortality (odds ratio [OR] 1.210, 95% CI 1.070 -1.360, P = 0.002). The volume of RBCs, fluids transfused, and the amount of vasoactive agents administered were not independent predictors. The area under the curve (AUC) of the ROC curve for intra-LAC for in-hospital mortality was 0.762 (95% confidence interval [CI], 0.711-0.812), with a cutoff value of 3.68 mmol/L by Youden index. CONCLUSIONS: Intraoperative lactate levels, but not hemodynamic management, were independently associated with increased in-hospital mortality after emergency GI surgery.

    DOI: 10.1186/s12893-023-02075-7

    PubMed

    researchmap

  • Hyaluronic Acid Restored Protein Permeability Across Injured Human Lung Microvascular Endothelial Cells 査読 国際誌

    Shinji Sugita, Yoshifumi Naito, Li Zhou, Hongli He, Qi Hao, Atsuhiro Sakamoto, Jae W. Lee

    FASEB BioAdvances   4 ( 9 )   619 - 631   2022年6月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Lung endothelial permeability is a key pathological feature of acute respiratory distress syndrome. Hyaluronic acid (HA), a major component of the glycocalyx layer on the endothelium, is generated by HA synthase (HAS) during inflammation and injury and is critical for repair. We hypothesized that administration of exogenous high molecular weight (HMW) HA would restore protein permeability across human lung microvascular endothelial cells (HLMVEC) injured by an inflammatory insult via upregulation of HAS by binding to CD44. A transwell coculture system was used to study the effects of HA on protein permeability across HLMVEC injured by cytomix, a mixture of IL-1β, TNFα, and IFNγ, with or without HMW or low molecular weight (LMW) HA. Coincubation with HMW HA, but not LMW HA, improved protein permeability following injury at 24 h. Fluorescence microscopy demonstrated that exogenous HMW HA partially prevented the increase in "actin stress fiber" formation. HMW HA also increased the synthesis of HAS2 mRNA expression and intracellular HMW HA levels in HLMVEC following injury. Pretreatment with an anti-CD44 antibody or 4-methylumbelliferone, a HAS inhibitor, blocked the therapeutic effects. In conclusion, exogenous HMW HA restored protein permeability across HLMVEC injured by an inflammatory insult in part through upregulation of HAS2.

    DOI: 10.1096/fba.2022-00006

    PubMed

    researchmap

  • Role of CD44 in increasing the potency of mesenchymal stem cell extracellular vesicles by hyaluronic acid in severe pneumonia 査読 国際誌

    Li Zhou, Qi Hao, Shinji Sugita, Yoshifumi Naito, Hongli He, Che-chung Yeh, Jae-Woo Lee

    Stem Cell Research & Therapy   12 ( 1 )   293 - 293   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title><sec>
    <title>Background</title>
    Although promising, clinical translation of human mesenchymal stem or stromal cell-derived extracellular vesicles (MSC EV) for acute lung injury is potentially limited by significant production costs. The current study was performed to determine whether pretreatment of MSC EV with high molecular weight hyaluronic acid (HMW HA) would increase the therapeutic potency of MSC EV in severe bacterial pneumonia.


    </sec><sec>
    <title>Methods</title>
    In vitro experiments were performed to determine the binding affinity of HMW HA to MSC EV and its uptake by human monocytes, and whether HMW HA primed MSC EV would increase bacterial phagocytosis by the monocytes. In addition, the role of CD44 receptor on MSC EV in the therapeutic effects of HMW HA primed MSC EV were investigated. In <italic>Pseudomonas aeruginosa</italic> (PA) pneumonia in mice, MSC EV primed with or without HMW HA were instilled intravenously 4 h after injury. After 24 h, the bronchoalveolar lavage fluid, blood, and lungs were analyzed for levels of bacteria, inflammation, MSC EV trafficking, and lung pathology.


    </sec><sec>
    <title>Results</title>
    MSC EV bound preferentially to HMW HA at a molecular weight of 1.0 MDa compared with HA with a molecular weight of 40 KDa or 1.5 MDa. HMW HA primed MSC EV further increased MSC EV uptake and bacterial phagocytosis by monocytes compared to treatment with MSC EV alone. In PA pneumonia in mice, instillation of HMW HA primed MSC EV further reduced inflammation and decreased the bacterial load by enhancing the trafficking of MSC EV to the injured alveolus. CD44 siRNA pretreatment of MSC EV prior to incubation with HMW HA eliminated its trafficking to the alveolus and therapeutic effects.


    </sec><sec>
    <title>Conclusions</title>
    HMW HA primed MSC EV significantly increased the potency of MSC EV in PA pneumonia in part by enhancing the trafficking of MSC EV to the sites of inflammation via the CD44 receptor on MSC EV which was associated with increased antimicrobial activity.


    </sec>

    DOI: 10.1186/s13287-021-02329-2

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1186/s13287-021-02329-2/fulltext.html

  • Therapeutic Effects of High Molecular Weight Hyaluronic Acid in Severe Pseudomonas Aeruginosa Pneumonia in Ex Vivo Perfused Human Lungs 査読 国際誌

    Xiwen Zhang, Shinji Sugita, Airan Liu, Yoshifumi Naito, Wonjung Hwang, Haibo Qiu, Atsuhiro Sakamoto, Teiji Sawa, Michael A. Matthay, Jae-Woo Lee

    American Journal of Physiology-Lung Cellular and Molecular Physiology   321 ( 5 )   L827-L836   2021年9月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Physiological Society  

    Introduction: We previously reported that extracellular vesicles (EVs) released during Escherichia coli bacterial pneumonia were inflammatory, and administration of high molecular weight hyaluronic acid (HMW HA) suppressed several indices of acute lung injury (ALI) from Escherichia coli pneumonia by binding to these inflammatory EVs. The current study was undertaken to study the therapeutic effects of HMW HA in ex vivo perfused human lungs injured with Pseudomonas aeruginosa (PA)103 bacterial pneumonia. Methods: For lungs with baseline alveolar fluid clearance (AFC)&lt;10%/h, HMW HA 1 or 2 mg was injected intravenously after 1 h (N = 4-9), and EVs released during PA pneumonia were collected from the perfusate over 6 h. For lungs with baseline AFC&gt;10%/h, HMW HA 2 mg was injected intravenously after 1 h (N = 6). In vitro experiments were conducted to evaluate the effects of HA on inflammation and bacterial phagocytosis. Results: For lungs with AFC&lt;10%/h, administration of HMW HA intravenously significantly restored AFC and numerically decreased protein permeability and alveolar inflammation from PA103 pneumonia but had no effect on bacterial counts at 6 h. However, HMW HA improved bacterial phagocytosis by human monocytes and neutrophils and suppressed the inflammatory properties of EVs released during pneumonia on monocytes. For lungs with AFC&gt;10%/h, administration of HMW HA intravenously improved AFC from PA103 pneumonia but had no significant effects on protein permeability, inflammation or bacterial counts. Discussion: In the presence of impaired alveolar epithelial transport capacity, administration of HMW HA improved the resolution of pulmonary edema from Pseudomonas PA103 bacterial pneumonia.

    DOI: 10.1152/ajplung.00626.2020

    PubMed

    researchmap

  • Therapeutic Effects of Hyaluronic Acid Against Cytotoxic Extracellular Vesicles Released During Pseudomonas Aeruginosa Pneumonia

    Yoshifumi Naito, Hideya Kato, Li Zhou, Shinji Sugita, Hongli He, Justin Zheng, Qi Hao, Teiji Sawa, Jae-Woo Lee

    Shock   57 ( 3 )   408 - 416   2021年8月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Ovid Technologies (Wolters Kluwer Health)  

    DOI: 10.1097/shk.0000000000001846

    PubMed

    researchmap

  • Therapeutic Effects of Hyaluronic Acid in Bacterial Pneumonia inEx VivoPerfused Human Lungs 査読 国際誌

    Airan Liu, Jeong-Hyun Park, Xiwen Zhang, Shinji Sugita, Yoshifumi Naito, Jae-Hoon Lee, Hideya Kato, Qi Hao, Michael A. Matthay, Jae-Woo Lee

    American Journal of Respiratory and Critical Care Medicine   200 ( 10 )   1234 - 1245   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Thoracic Society  

    Rationale: Recent studies have demonstrated that extracellular vesicles (EVs) released during acute lung injury (ALI) were inflammatory.Objectives: The current study was undertaken to test the role of EVs induced and released from severe Escherichia coli pneumonia (E. coli EVs) in the pathogenesis of ALI and to determine whether high-molecular-weight (HMW) hyaluronic acid (HA) administration would suppress lung injury from E. coli EVs or bacterial pneumonia.Methods: E. coli EVs were collected from the perfusate of an ex vivo perfused human lung injured with intrabronchial E. coli bacteria for 6 hours by ultracentrifugation and then given intrabronchially or intravenously to naive human lungs. One hour later, HMW HA was instilled into the perfusate (n = 5-6). In separate experiments, HMW HA was given after E. coli bacterial pneumonia (n = 6-10). In vitro experiments were conducted to evaluate binding of EVs to HMW HA and uptake of EVs by human monocytes.Measurements and Main Results: Administration of HMW HA ameliorated the impairment of alveolar fluid clearance, protein permeability, and acute inflammation from E. coli EVs or pneumonia and reduced total bacteria counts after E. coli pneumonia. HMW HA bound to E. coli EVs, inhibiting the uptake of EVs by human monocytes, an effect associated with reduced TNFα (tumor necrosis factor α) secretion. Surprisingly, HMW HA increased E. coli bacteria phagocytosis by monocytes.Conclusions: EVs induced and released during severe bacterial pneumonia were inflammatory and induced ALI, and HMW HA administration was effective in inhibiting the uptake of EVs by target cells and decreasing lung injury from E. coli EVs or bacterial pneumonia.

    DOI: 10.1164/rccm.201812-2296oc

    PubMed

    researchmap

  • Dose of intraoperative remifentanil administration is independently associated with increase in the risk of postoperative nausea and vomiting in elective mastectomy under general anesthesia 査読 国際誌

    Jun Hozumi, Moritoki Egi, Shinji Sugita, Tetsufumi Sato

    Journal of Clinical Anesthesia   34   227 - 231   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    BACKGROUND: Postoperative nausea and vomiting (PONV) is one of the common complications in patients who have undergone surgery with general anesthesia. The association of intraoperative use of remifentanil with PONV has remained controversial. The aim of the current study was to determine the association of dose of intraoperative remifentanil administration with incidence of PONV. METHODS: The present study was a single-center retrospective observational study and included 423 female patients with American Society of Anesthesiologists physical status I or II who underwent elective mastectomy under general anesthesia between October 2011 and October 2012. The incidence of PONV within 3 days after the operation was prospectively assessed. The time-weighted average of remifentanil during the operation (twRem) was calculated. We used a multivariate regression model to assess the independent association of the twRem with the incidence of PONV. RESULTS: Among 423 patients, 129 patients (30.5%) had PONV during the study period. Remifentanil was administrated in 355 patients (83.9%). In the multivariate logistic regression model using categories of twRem, we found that increased twRem was independently associated with increase in the risk of PONV (P=.01). There was an independent association between twRem greater than 0.2 μg/kg per minute and increase in the risk of PONV. CONCLUSION: This retrospective observational study revealed a dose-dependent association between dose of intraoperative remifentanil administration and increase in the risk of PONV. Time-weighted average of remifentanil greater than 0.2 μg/kg per minute was independently associated with risk of PONV.

    DOI: 10.1016/j.jclinane.2016.04.018

    PubMed

    researchmap

  • 集中治療のシミュレーショントレーニングコースの必要性に関するアンケート調査

    梅井 菜央, Benjamin Berg, 市場 晋吾, 竹田 晋浩, 杉田 慎二, 坂本 篤裕

    日本集中治療医学会雑誌   23 ( Suppl. )   332 - 332   2016年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    researchmap

  • 肺移植のbridgeとしてECMO管理を行った患者における看護実践の経験 査読

    中山 誠一, 大野 綾子, 足立 圭, 亀ヶ谷 泰匡, 細萱 順一, 背戸 陽子, 鈴木 健一, 杉田 慎二, 市場 晋吾, 竹田 晋浩

    日本集中治療医学会雑誌   23 ( Suppl. )   763 - 763   2016年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    researchmap

  • Extracorporeal membrane oxygenation(ECMO)が有効であった肥満肺胞低換気症候群に伴う重症呼吸不全の一例 査読

    梅井 菜央, 市場 晋吾, 竹田 晋浩, 杉田 慎二, 田邉 三思, 坂本 篤裕

    日本救急医学会雑誌   26 ( 8 )   450 - 450   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

    researchmap

  • 新しいECMO装置Cardiohelp systemの耐久性について 査読

    市場 晋吾, 竹田 晋浩, 梅井 菜央, 田邉 三思, 杉田 慎二, 坂本 篤裕

    日本救急医学会雑誌   26 ( 8 )   449 - 449   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

    researchmap

  • Continuous Infusion of Dexmedetomidine Improves Renal Ischemia-reperfusion Injury in Rat Kidney 査読

    Sugita Shinji, Okabe Tadashi, Sakamoto Atsuhiro

    Journal of Nippon Medical School   80 ( 2 )   131 - 139   2013年

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:The Medical Association of Nippon Medical School  

    Background: Dexmedetomidine has shown beneficial effects in several inflammatory models, including ischemia-reperfusion injury (IRI). This study investigated whether the continuous infusion of dexmedetomidine could improve renal IRI in rats.<br> Methods: Rats were subjected to either a sham operation and given pentobarbital (10 mg/kg/h; n=6) or were subjected to 45 minutes of renal ischemia and anesthetized with pentobarbital (10 mg/kg/h; n=6), dexmedetomidine (10 or 20 μg/kg/h; both n=6), or both pentobarbital (10 mg/kg/h) and dexmedetomidine (1.0 μg/kg/h; n=6) for 6 hours of reperfusion. Blood urea nitrogen and serum creatinine were measured 6 hours after reperfusion. Gene expression mediated by inflammatory systems in the kidney was measured with the real-time reverse-transcriptase polymerase chain reaction.<br> Results: Treatment with 10 or 20 μg/kg/h of dexmedetomidine reduced renal dysfunction. The increases in the messenger RNA expression of interleukin-6, intercellular adhesion molecule 1, and inducible nitric oxide synthase caused by renal IRI were suppressed. Under In rats under pentobarbital anesthesia, 1.0 μg/kg/h of dexmedetomidine also improved renal dysfunction after renal IRI.<br> Conclusion: The present study demonstrates that continuous infusion of dexmedetomidine improves renal IRI. Moreover, with pentobarbital anesthesia, a dose of dexmedetomidine lower than the sedative dose also improves renal IRI.<br>

    DOI: 10.1272/jnms.80.131

    researchmap

▼全件表示

書籍等出版物

  • 呼吸ECMOマニュアル

    氏家良人, 市場晋吾, 竹田晋浩( 担当: 分担執筆 範囲: respiratoryECMO の歴史と我が国の現状)

    2014年 

     詳細を見る

  • 呼吸管理における 5years 文献レビュー

    氏家良人( 担当: 分担執筆 範囲: 重症呼吸不全に対する ECMO 療法)

    2014年 

     詳細を見る

  • ME 機器 安全使用・管理マ ニュアル 虎の巻:国家試験取得から臨床現場における ME 機器の使用目的,操作方法,トラブル対処まで

    坂本篤裕, 竹田晋浩, 鈴木健一( 担当: 分担執筆 範囲: PCPS/ECMO (成人))

     詳細を見る

MISC

  • 急性呼吸窮迫症候群における高分子ヒアルロン酸の治療効果 ; ヒト肺生体外灌流モデルを中心とした研究

    杉田慎二

    日本医科大学医学会雑誌   17 ( 4 )   243 - 244   2021年

     詳細を見る

  • Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease

    Airan Liu, Xiwen Zhang, Hongli He, Li Zhou, Yoshifumi Naito, Shinji Sugita, Jae-Woo Lee

    Expert Opinion on Biological Therapy   20 ( 2 )   125 - 140   2020年2月

     詳細を見る

    出版者・発行元:Informa UK Limited  

    DOI: 10.1080/14712598.2020.1689954

    researchmap

  • 当院で経験した呼吸不全に対する長期VV‐ECMO患者の肺移植登録についての検討

    杉田慎二, 竹田晋浩, 梅井菜央, 市場晋吾, 坂本篤裕

    日本集中治療医学会学術集会(Web)   43rd ( Suppl. )   DP20‐6 (WEB ONLY) - 545   2016年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    J-GLOBAL

    researchmap

  • 致死的気道閉塞の治療にVeno‐Venous Extracorporeal Membrane Oxygenation(VV‐ECMO)を使用し救命した一例

    永本盛嗣, 梅井菜央, 市場晋吾, 杉田慎二, 竹田晋浩, 坂本篤裕

    日本集中治療医学会学術集会(Web)   43rd ( Suppl. )   O4‐2 (WEB ONLY) - 400   2016年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    J-GLOBAL

    researchmap

  • ECMOによる肺保護戦略

    市場晋吾, 梅井菜央, 杉田慎二

    日本集中治療医学会学術集会(Web)   43rd   SY1‐4 (WEB ONLY)   2016年1月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 血液悪性腫瘍患者の重症呼吸不全3症例に対してのECMO使用の検討

    森田 智教, 杉田 慎二, 竹田 晋浩, 坂本 篤裕

    日本集中治療医学会雑誌   23 ( Suppl. )   599 - 599   2016年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    researchmap

  • 周術期 ハイリスク患者の管理 / 透析・慢性腎不全の患者

    杉田 慎二, 市場 晋吾

    臨床泌尿器科 増刊号特集 泌尿器科処方のすべて─すぐに使える実践ガイド   70 ( 4 )   268 - 271   2016年

     詳細を見る

  • ECMO治療における人工肺の種類による管理方法の違いについての検討

    内田千草, 鈴木健一, 梅井菜央, 杉田慎二, 市場晋吾, 竹田晋浩

    人工臓器(日本人工臓器学会)   44 ( 2 )   S.142 - 142   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本人工臓器学会  

    J-GLOBAL

    researchmap

  • 最新のECMO療法 ECMOプロジェクト発足後における当院での心臓血管手術に対するECMO療法

    杉田 慎二, 梅井 菜央, 市場 晋吾, 竹田 晋浩

    日本臨床麻酔学会誌   35 ( 6 )   S199 - S199   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床麻酔学会  

    researchmap

  • 熱傷・外傷・体外循環 重症呼吸不全に対するECMO患者のモニタリング

    市場晋吾, 林久美子, 平山隆浩, 梅井菜央, 杉田慎二, 竹田晋浩

    救急・集中治療   27 ( 5-6 )   444 - 453   2015年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:総合医学社  

    CiNii Books

    J-GLOBAL

    researchmap

  • ARDSに対するECMO (特集 ARDS : 『七転び八起き』最新事情)

    市場 晋吾, 梅井 菜央, 杉田 慎二

    救急医学 = The Japanese journal of acute medicine   39 ( 6 )   679 - 687   2015年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:へるす出版  

    researchmap

  • ANCA関連血管炎に対してECMOと理学療法が奏功した一例

    永田 紗弥子, 竹田 寛恵, 森 啓介, 杉田 慎二, 小林 克也, 竹田 晋浩, 坂本 篤裕

    日本集中治療医学会雑誌   22 ( Suppl. )   [DP129 - 4]   2015年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

    researchmap

  • ECMO の現状と将来

    杉田慎二, 小林克也, 竹田晋浩

    救急・集中治療「症例と Q & A で学ぶ最新の ECMO」   26 ( 11/12 )   1409 - 1414   2014年

     詳細を見る

  • 心不全患者における鎮静

    杉田 慎二, 小林 克也, 竹田 晋浩

    ICU と CCU   38 ( 12 )   813 - 818   2014年

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015076514

  • ECMO の有用性について

    杉田慎二, 小林克也, 竹田晋浩

    呼吸と循環   62 ( 4 )   381 - 385   2014年

     詳細を見る

  • 非侵襲的陽圧換気と高流量経鼻酸素療法

    杉田慎二, 小林克也, 竹田晋浩

    救急・集中治療「人工呼吸管理―その常識は正しいか? ―」   26 ( 9/10 )   1185 - 1192   2014年

     詳細を見る

  • 重症肺炎に対する体外式膜型人工肺(ECMO)療法

    杉田慎二, 小林克也, 竹田晋浩

    medicina   2028 - 2030   2013年

     詳細を見る

  • 硬膜穿刺後頭痛

    岸川洋昭, 竹内純平, 永田紗弥子, 永井瑞希, 鈴木規仁, 武藤友美, 田中俊輔, 石川真士, 源田雄紀, 安齋めぐ み, 原田里音, 杉田慎二, 保利陽子, 八木 馨, 後藤玄太郎, その

    臨床麻酔   37 ( 9 )   1375 - 1381   2013年

     詳細を見る

▼全件表示

講演・口頭発表等

受賞

  • Kosaka Best of Meeting Award Top Finalist – Scholars

    2019年   Therapeutic Effects of High Molecular Weight Hyaluronic Acid in Ex Vivo Perfused Marginal Human Lungs Injured with Pseudomonas Aeruginosa.

     詳細を見る

共同研究・競争的資金等の研究課題

  • HAS2/HAS2-AS1/HMGA2 axis によるARDSの制御

    研究課題/領域番号:21K09086  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    杉田 慎二, 坂本 篤裕, 石川 真士

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    急性呼吸促迫症候群(ARDS)は、様々な疾患に起因する、急性肺障害の最重症の疾患で、肺胞や微小血管のバ リア機能が障害さ れ、肺胞に著明な浮腫を起こし、肺胞のガス交換が阻害され、重度の低酸素血症 となる。
    血管バリア機能の維持にヒアルロン酸合成が関与している可能性があり、ヒアルロン合成を制御するHAS2/HAS2-AS1/HMGA2 axis の役割を明らかにするために、3年間の研究計画を遂行中である。
    1年目では、ヒト肺微小血管内皮細胞(HLMVECs)を用いて、サイトカイン暴露におけるHAS2/HAS2-AS1/HMGA2 axis の経時的発現変化、ウ ェスタンブロット によってタンパク質発現を、qPCR によって遺伝子発現の変化が生じることを確認した。これらの発現変化はヒアルロン酸の受容体でもあるCD44によって調節されている可能性も示唆された。ただし、これらの発現の変化は細胞の状態や細胞障害の強さに依存している可能性も考えられたため、より臨床的に妥当性のある実験プロトコールを確立する必要がある。
    HAS2/HAS2-AS1/HMGA2 axis の経時的発現変化を制御することが真に細胞障害における血管バリアを調整するかを確認するために、2年目以降はトランスフェクション実験を行うことで検証していく。これまでの結果などは研究計画に則って、2年目以降に学会で発表をしていく予定である。

    researchmap